###begin article-title 0
###xml 69 73 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 79 83 <span type="species:ncbi:10090">Mice</span>
Adiponectin Haploinsufficiency Promotes Mammary Tumor Development in MMTV-PyVT Mice by Modulation of Phosphatase and Tensin Homolog Activities
###end article-title 0
###begin p 1
Conceived and designed the experiments: AX YW. Performed the experiments: JBL KHC JL YW. Analyzed the data: JBL KHC AX YW. Contributed reagents/materials/analysis tools: AX KL NSW RTM PS GC YW. Wrote the paper: JBL KHC YW.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Adiponectin is an adipokine possessing beneficial effects on obesity-related medical complications. A negative association of adiponectin levels with breast cancer development has been demonstrated. However, the precise role of adiponectin deficiency in mammary carcinogenesis remains elusive.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 22 26 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 58 62 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 69 84 <span type="species:ncbi:10090">transgenic mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 491 495 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 640 649 <span type="species:ncbi:10090">nude mice</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
In the present study, MMTV-polyomavirus middle T antigen (MMTV-PyVT) transgenic mice with reduced adiponectin expressions were established and the stromal effects of adiponectin haploinsufficiency on mammary tumor development evaluated. In mice from both FVB/N and C57BL/6J backgrounds, insufficient adiponectin production promoted mammary tumor onset and development. A distinctive basal-like subtype of tumors, with a more aggressive phenotype, was derived from adiponectin haplodeficient MMTV-PyVT mice. Comparing with those from control MMTV-PyVT mice, the isolated mammary tumor cells showed enhanced tumor progression in re-implanted nude mice, accelerated proliferation in primary cultures, and hyperactivated phosphatidylinositol-3-kinase (PI3K)/Akt/beta-catenin signaling, which at least partly attributed to the decreased phosphatase and tensin homolog (PTEN) activities. Further analysis revealed that PTEN was inactivated by a redox-regulated mechanism. Increased association of PTEN-thioredoxin complexes was detected in tumors derived from mice with reduced adiponectin levels. The activities of thioredoxin (Trx1) and thioredoxin reductase (TrxR1) were significantly elevated, whereas treatment with either curcumin, an irreversible inhibitor of TrxR1, or adiponectin largely attenuated their activities and resulted in the re-activation of PTEN in these tumor cells. Moreover, adiponectin could inhibit TrxR1 promoter-mediated transcription and restore the mRNA expressions of TrxR1.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
Adiponectin haploinsufficiency facilitated mammary tumorigenesis by down-regulation of PTEN activity and activation of PI3K/Akt signalling pathway through a mechanism involving Trx1/TrxR1 redox regulations.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 104 107 104 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Pischon1">[1]</xref>
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-McTiernan1">[2]</xref>
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Bray1">[3]</xref>
###xml 402 405 402 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Housa1">[4]</xref>
###xml 407 410 407 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Baillargeon1">[5]</xref>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Berstein1">[6]</xref>
###xml 417 420 417 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Rose1">[7]</xref>
###xml 642 645 642 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang1">[8]</xref>
###xml 647 650 647 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Trujillo1">[9]</xref>
###xml 883 887 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Barb1">[10]</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Schaffler1">[11]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-VonaDavis1">[12]</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang2">[13]</xref>
###xml 907 911 907 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Mistry1">[14]</xref>
###xml 913 917 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Kelesidis1">[15]</xref>
###xml 919 923 919 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Koerner1">[16]</xref>
###xml 1196 1200 1196 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Kaklamani1">[17]</xref>
###xml 1202 1206 1202 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Korner1">[18]</xref>
###xml 1208 1212 1208 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Mantzoros1">[19]</xref>
###xml 1214 1218 1214 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Tian1">[20]</xref>
###xml 1220 1224 1220 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Tworoger1">[21]</xref>
###xml 1226 1230 1226 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Miyoshi1">[22]</xref>
###xml 1232 1236 1232 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Chen1">[23]</xref>
###xml 1238 1242 1238 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Kang1">[24]</xref>
###xml 990 995 <span type="species:ncbi:9606">women</span>
###xml 1129 1134 <span type="species:ncbi:9606">women</span>
###xml 1280 1285 <span type="species:ncbi:9606">women</span>
The prevalence of obesity and obesity-related cancers has risen alarmingly for the past several decades [1], [2], [3]. Unfortunately, the mechanisms underlying the association between obesity and cancer are not well understood. Recent evidences suggest that adipokines, referring to a group of secreted factors from adipose tissue, could be the key players in regulating obesity-related carcinogenesis [4], [5], [6], [7]. Adiponectin is an abundant adipocyte-derived hormone that can elicit pleiotropic beneficial functions against obesity-related medical conditions, such as diabetes, chronic inflammation, atherosclerosis and tumorigenesis [8], [9]. Decreased circulating concentrations of adiponectin are associated with many obesity-related cancer diseases, including breast cancer, endometrial cancer, gastric cancer, colorectal cancer, renal cell carcinoma and prostate cancer [10], [11], [12], [13], [14], [15], [16]. Breast cancer represents the second leading cause of death among women. An inverse correlation of circulating adiponectin levels with breast cancer risk has been observed in both pre- and post-menopausal women, independent of body mass index and other known risk factors [17], [18], [19], [20], [21], [22], [23], [24]. Moreover, mammary tumors arising in women with low serum adiponectin levels are more likely to show a biologically aggressive and poor prognosis phenotype. These epidemiological evidences suggest that reduced adiponectin expression might be causally involved in obesity-related carcinogenesis.
###end p 9
###begin p 10
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Pfeiler1">[25]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Grossmann1">[26]</xref>
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Arditi1">[27]</xref>
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Dieudonne1">[29]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Kang2">[30]</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Nakayama1">[31]</xref>
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Hebbard1">[32]</xref>
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Jarde1">[33]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 845 849 845 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Dieudonne1">[29]</xref>
###xml 990 994 990 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Korner1">[18]</xref>
###xml 996 1000 996 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 1132 1136 1132 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Grossmann1">[26]</xref>
###xml 1275 1279 1275 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 368 373 <span type="species:ncbi:9606">human</span>
###xml 579 588 <span type="species:ncbi:10090">nude mice</span>
In line with these clinical findings, numerous experimental evidences support the role of adiponectin as an inhibitory factor for breast cancer development [25], [26], [27], [28], [29], [30], [31], [32], [33]. Adiponectin at physiological concentrations suppresses the proliferation and causes cell cycle arrest in both estrogen receptor (ER)-negative and ER-positive human breast carcinoma cells. It inhibits insulin- and growth factors-stimulated growth of ER-positive breast cancer cells [28]. Adiponectin replenishment suppresses mammary tumorigenesis of MDA-MB-231 cells in nude mice [28]. Cell-type dependent signalling mechanisms have been suggested to mediate the growth inhibitory effects of adiponectin. In MCF-7 cells, adiponectin induces AMP-activated protein kinase (AMPK) phosphorylation and inactivates p42/p44 MAPkinase (ERK1/2) [29]. By contrast, the inhibitory effects of adiponectin on T47D cell growth are associated with inactivation of ERK1/2 but not AMPK or p38 MAPK [18], [28]. In MDA-MB-231 cells with ectopic ER over-expression, globular adiponectin inhibits cell proliferation by blocking JNK2 signalling [26]. In ER-negative MDA-MB-231 cells, adiponectin could modulate the glycogen synthase kinase-3beta (GSK3beta)/beta-catenin signaling pathway [28]. Prolonged treatment with adiponectin markedly reduces serum-induced phosphorylation of GSK3beta, decreases intracellular accumulation and nuclear translocation of beta-catenin, and suppresses cyclin D1 expression. Despite of these progresses, whether adiponectin deficiency is a direct contributor to the pathogenesis of breast cancer remain elusive.
###end p 10
###begin p 11
###xml 109 113 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 119 134 <span type="species:ncbi:10090">transgenic mice</span>
###xml 136 140 <span type="species:ncbi:10090">Mice</span>
In this study, we investigated the effects of reduced adiponectin expression on mammary tumor development in MMTV-PyVT transgenic mice. Mice with reduced adiponectin expressions were established in both FVB/N and C57BL/6J backgrounds. Adiponectin haploinsufficiency significantly reduced tumor latency and promoted mammary tumor development in both female and male animals. The results demonstrated that inadequate adiponectin production might alter the stromal microenvironment towards more pro-proliferative and pro-tumorigenic in mammary tissue, by triggering the abnormal redox activities that led to the inhibition of tumor suppressor PTEN and hyperactivation of PI3K/Akt signaling pathways in mammary tumor cells.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 69 73 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice
###end title 13
###begin p 14
###xml 330 339 330 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(&#8722;/&#8722;)</italic>
###xml 377 395 377 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 408 426 408 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 553 561 553 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g001">Figure 1</xref>
###xml 888 896 888 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g002">Figure 2</xref>
###xml 942 960 942 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1116 1134 1116 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1683 1691 1683 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g003">Figure 3</xref>
###xml 1718 1727 1718 1727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(&#8722;/&#8722;)</italic>
###xml 1907 1925 1907 1925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1993 2011 1993 2011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 2095 2102 2095 2102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004968-t001">Table 1</xref>
###xml 2223 2231 2221 2229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/&#8722;)</italic>
###xml 2271 2279 2267 2275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/+)</italic>
###xml 2398 2406 2392 2400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/&#8722;)</italic>
###xml 2454 2462 2446 2454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/+)</italic>
###xml 2551 2560 2543 2552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)</italic>
###xml 2608 2617 2600 2609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(&#8722;/&#8722;)</italic>
###xml 13 17 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 23 38 <span type="species:ncbi:10090">transgenic mice</span>
###xml 121 136 <span type="species:ncbi:10090">transgenic mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 961 965 <span type="species:ncbi:10090">mice</span>
###xml 1050 1054 <span type="species:ncbi:10090">mice</span>
###xml 1135 1139 <span type="species:ncbi:10090">mice</span>
###xml 1184 1188 <span type="species:ncbi:10090">mice</span>
###xml 1269 1273 <span type="species:ncbi:10090">mice</span>
###xml 1382 1386 <span type="species:ncbi:10090">mice</span>
###xml 1476 1480 <span type="species:ncbi:10090">mice</span>
###xml 1664 1668 <span type="species:ncbi:10090">mice</span>
###xml 1728 1732 <span type="species:ncbi:10090">mice</span>
###xml 1890 1894 <span type="species:ncbi:10090">mice</span>
###xml 1926 1930 <span type="species:ncbi:10090">mice</span>
###xml 2012 2016 <span type="species:ncbi:10090">mice</span>
###xml 2142 2146 <span type="species:ncbi:10090">mice</span>
###xml 2319 2323 <span type="species:ncbi:10090">mice</span>
###xml 2561 2565 <span type="species:ncbi:10090">mice</span>
###xml 2618 2622 <span type="species:ncbi:10090">mice</span>
###xml 2687 2691 <span type="species:ncbi:10090">mice</span>
We generated MMTV-PyVT transgenic mice with reduced adiponectin expressions in both FVB/N and C57BL/6J backgrounds. PyVT transgenic mice with complete loss of the adiponectin alleles could not be born alive across all generations due to embryonic lethality. On the other hand, the knockout genotypes were found in male and female PyVT(-/-) litters. Therefore, mice with normal PyVT(+/-)/ADN(+/+) and reduced PyVT(+/-)/ADN(+/-) adiponectin expressions were used in the present study. The heterozygotes showed a 4-5 folds reduction of adiponectin levels (Figure 1), which were more relevant to those breast cancer patients with decreased adiponectin levels. Tumor development of these mice was closely monitored every 2-3 days. All mice carrying the PyVT transgene developed mammary tumors. Tumor onset was recorded as the age of the animal at which palpable abnormal masses were detected (Figure 2). The overall median age of tumor latency in PyVT(+/-)/ADN(+/-) mice of FVB/N background were 58 days for female (n = 20) and 115 days for male (n = 23) mice respectively, which were significantly earlier than those of PyVT(+/-)/ADN(+/+) mice (66 days for female and 133.5 days for male mice, n = 23 and 24 respectively, p<0.0001). Similar phenomena were also observed in mice of C57BL/6J background. The overall median tumor latency of female and male adiponectin haplodeficient PyVT mice (66 and 114 days respectively, n = 19) was significantly reduced comparing with those of mice having normal adiponectin expression levels (73 and 137 days respectively, n = 19, p<0.0001). Tumor development was monitored twice per week up to 14 and 28 weeks for female and male mice respectively (Figure 3). No tumors were found in PyVT(-/-) mice up to 60 weeks, irrespective of their adiponectin levels. Tumor growth was significantly accelerated in both female and male adiponectin haplodeficient PyVT mice compared to PyVT(+/-)/ADN(+/+) mice. At the time of sacrifice, the total wet weights of tumors in PyVT(+/-)/ADN(+/-) mice was over 2-fold heavier than those with normal adiponectin expression levels (Table 1). The mean tumor weight of female PyVT mice of FVB/N background when sacrificed at 14 wks of age was 9.889+/-3.189 g in ADN(+/-) animals compared to 4.483+/-1.645 g in ADN(+/+) animals. Similarly, in male FVB/N PyVT mice sacrificed at 22 wks of age, the mean tumor weight was 6.857+/-1.262 g in ADN(+/-) animals compared to that of 3.687+/-1.483 g in ADN(+/+) animals. On the other hand, although the wet weights of lung tissues in female and male PyVT(+/-) mice were heavier than those in non-transgenic PyVT(-/-) mice (data not shown), they were not significantly different between mice with reduced and normal adiponectin expressions.
###end p 14
###begin title 15
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Serum adiponectin distributions in wildtype and PyVT mice.
###end title 15
###begin p 16
###xml 158 162 <span type="species:ncbi:10090">mice</span>
The serum adiponectin concentrations were measured by an in-house sandwich ELISA assay using blood samples collected from the tail vein of FVB/N and C57BL/6J mice. The median and mean values were calculated and displayed in the table.
###end p 16
###begin title 17
###xml 52 56 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Reduced tumor latency in adiponectin haplodeficient MMTV-PyVT mice of both FVB/N and C57BL/6J genetic backgrounds.
###end title 17
###begin p 18
###xml 495 503 495 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/+)</italic>
###xml 508 516 508 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/&#8722;)</italic>
The tumor onset was closely monitored by visual inspection and palpation every 2-3 days. Latency of mammary tumors was defined as the age when a palpable lump was first detected in the mammary gland. Kaplan-Meier estimates of the tumor-free survival curves were calculated and plotted. Median value represents the time point when 50% of animals developed palpable tumor masses. The significance of differences in latency was analyzed by the Log-rank test. The comparisons were performed between ADN(+/+) and ADN(+/-) female (left panel) and male (right panel) animals in FVB/N and C57BL/6J genetic backgrounds. CI, confidence interval.
###end p 18
###begin title 19
###xml 68 72 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Accelerated mammary tumor development in adiponectin haplodeficient MMTV-PyVT mice.
###end title 19
###begin p 20
###xml 16 34 16 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 39 57 39 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 285 292 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
Tumor growth in PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice were monitored starting from 6 and 11 wks, up to 14 and 28 wks for female (left panel) and male (right panel) mice respectively. Tumor sizes were measured using vernier calipers and tumor volume calculated as described in Methods. Each group contained 13-20 mice, and the mean tumor volume +/-SD was presented.
###end p 20
###begin title 21
###xml 59 77 59 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 82 100 82 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Total wet weights of tumor and lung tissues collected from PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice in FVB/N and C57BL/6J background.
###end title 21
###begin p 22
###xml 28 46 28 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
p<0.05 vs the corresponding PyVT(+/-)/ADN(+/+) mice group.
###end p 22
###begin title 23
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Distinct basal-like subtype of tumors in adiponectin haplodeficient PyVT mice
###end title 23
###begin p 24
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Sorlie1">[42]</xref>
###xml 371 389 371 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 429 447 429 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 646 664 646 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 709 714 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT17</italic>
###xml 716 720 716 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRT5</italic>
###xml 722 727 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MFGE8</italic>
###xml 732 736 732 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FZD7</italic>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2</italic>
###xml 822 826 822 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MED1</italic>
###xml 862 871 862 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g004">Figure 4A</xref>
###xml 1168 1186 1168 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1192 1196 1192 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Livasy1">[43]</xref>
###xml 1198 1207 1198 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g004">Figure 4B</xref>
###xml 1269 1287 1269 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1610 1628 1610 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1651 1669 1651 1669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1678 1687 1678 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g004">Figure 4C</xref>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 1187 1191 <span type="species:ncbi:10090">mice</span>
###xml 1288 1292 <span type="species:ncbi:10090">mice</span>
###xml 1314 1318 <span type="species:ncbi:10090">mice</span>
Five subtypes of breast carcinoma with different outcomes, including luminal A, luminal B, HER2+/ER-, basal-like and normal breast-like, were revealed by microarray studies [42]. Luminal A and B are ER positive tumors, whereas the other three subtypes are ER negative. Our preliminary microarray analysis suggested that the molecular profiles of tumor cells derived from PyVT(+/-)/ADN(+/-) mice were very different from those of PyVT(+/-)/ADN(+/+) mice and could be clustered separately (data not shown). To further validate such an observation, gene markers associated with different tumor subtypes were quantified by real-time PCR analysis. In PyVT(+/-)/ADN(+/-) tumors, basal-like subtype genes, including KRT17, KRT5, MFGE8 and FZD7, were significantly up-regulated, whereas HER2+/ER- subtype-related genes, ERBB2 and MED1, were dramatically down-regulated (Figure 4A). Histological analysis demonstrated typical morphologic features associated with the basal-like subtype, including markedly elevated geographic tumor necrosis, ribbon-like architecture associated with central necrosis, pushing margin of invasion, and stromal lymphocytic response in tumors from PyVT(+/-)/ADN(+/-) mice [43] (Figure 4B). We could not detect these morphological features in any of PyVT(+/-)/ADN(+/+) mice or the original PyVT mice, which in contrast showed a well-structured and organized morphology, suggesting that the phenotype differences may not be tumor developmental stage dependent. Moreover, the protein levels of p53, a characteristic associated with tumors overexpressing ERBB2, was significantly higher in the PyVT(+/-)/ADN(+/+) tumors comparing with PyVT(+/-)/ADN(+/-) tumors (Figure 4C). These and the above evidence suggested that adiponectin deficiency might result in the development of a basal-like subtype tumor, which could be aroused from a different origin or subgroups of stem cells that developed tumor more aggressively.
###end p 24
###begin title 25
###xml 79 83 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
A basal-like subtype of mammary tumors derived from adiponectin haplodeficient MMTV-PyVT mice.
###end title 25
###begin p 26
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 208 226 208 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 231 249 231 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 328 335 328 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 350 368 350 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 452 470 452 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 475 493 475 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 801 819 801 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 826 827 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 895 913 895 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 944 962 944 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 914 918 <span type="species:ncbi:10090">mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
A, Quantitative RT-PCR analysis of the expression levels of gene markers associated with different subtypes of breast tumors. The RNA was extracted from cultured primary tumor cells isolated from 14-week old PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) female FVB/N mice and quantitative PCR analysis performed as described in the Methods. *, P<0.01 vs PyVT(+/-)/ADN(+/+) group, n = 10. B, Morphological features of tumors derived from 14-week old female PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice of the FVB/N background. Distinct morphologies were observed between tumors collected from mice with normal and reduced adiponectin levels. Note that central necrosis and geographic tumor necrosis, as well as stromal lymphocytic responses represented the typical basal-like subtype of breast tumors in PyVT(+/-)/ADN(+/-) mice. C, The protein levels of p53 were much higher in tumors derived from PyVT(+/-)/ADN(+/+) mice compared to those of the PyVT(+/-)/ADN(+/-) mice as measured by Western Blotting using specific antibodies purchased from Cell Signaling Biotechnology.
###end p 26
###begin title 27
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Accelerated growth of primary tumor cells derived from adiponectin haplodeficient mice
###end title 27
###begin p 28
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Varticovski1">[39]</xref>
###xml 785 802 785 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g005">Figure 5, A and B</xref>
###xml 1136 1154 1136 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1187 1205 1187 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1212 1219 1212 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004968-t002">Table 2</xref>
###xml 1442 1450 1442 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/&#8722;)</italic>
###xml 1456 1464 1456 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/+)</italic>
###xml 1604 1622 1592 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1658 1676 1646 1664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1683 1691 1671 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g003">Figure 3</xref>
###xml 1828 1836 1816 1824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g005">Figure 5</xref>
###xml 2222 2240 2210 2228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 2245 2263 2233 2251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 2327 2334 2315 2322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004968-t002">Table 2</xref>
###xml 2453 2471 2441 2459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 2625 2633 2613 2621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g006">Figure 6</xref>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 109 118 <span type="species:ncbi:10090">nude mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 443 448 <span type="species:ncbi:10090">mouse</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 935 944 <span type="species:ncbi:10090">nude mice</span>
###xml 1155 1159 <span type="species:ncbi:10090">mice</span>
###xml 1206 1210 <span type="species:ncbi:10090">mice</span>
###xml 1345 1354 <span type="species:ncbi:10090">nude mice</span>
###xml 1677 1681 <span type="species:ncbi:10090">mice</span>
###xml 1736 1745 <span type="species:ncbi:10090">nude mice</span>
###xml 2013 2017 <span type="species:ncbi:10090">mice</span>
###xml 2185 2194 <span type="species:ncbi:10090">nude mice</span>
###xml 2423 2432 <span type="species:ncbi:10090">nude mice</span>
We next isolated the primary tumor cells from the PyVT mice, and examined their tumor development in athymic nude mice following the protocol described previously [39]. Since tumors originated from different torso regions of PyVT mice might show various degrees of aggressiveness and onset latencies, we collected only tumors from the axillary mammary glands and re-implanted the isolated tumor cells into the posterior glands of athymic nude mouse by intraductal inoculation. The transplantation was reproducible and tumor growth rate correlated with the number of transplanted cells. Consistent with those observed in PyVT mice, the tumor development of cells derived from adiponectin haplodeficient mice was more aggressive than those from mice with normal adiponectin expressions (Figure 5, A and B). The accelerated tumor growth was reproducibly observed even when the cells were re-implanted for multiple times in new batches of nude mice (data not shown), suggesting that serial transplantation preserved the molecular characteristics of the tumor origin. At the time of sacrifice, the total weights of the collected tumors from PyVT(+/-)/ADN(+/-) mice were heavier than those of PyVT(+/-)/ADN(+/+) mice (Table 2). Note that when the tumor cells were exposed to physiological adiponectin secreted from adipocytes in the mammary tissue of nude mice, the change in the tumor volume was smaller, but still significantly different between ADN(+/-) with ADN(+/+) groups. At approximately3 weeks after tumor occurrence, the measurable tumor volumes were 5.5 and 2.8 fold higher in FVB/N male and female PyVT(+/-)/ADN(+/-) animals respectively than those of PyVT(+/-)/ADN(+/+) mice (Figure 3), whereas the differences for the implanted nude mice were approximately 3.2 and 2.1 fold for male and female tumor cells respectively (Figure 5). The results further suggest that the magnitude of tumor growth could be suppressed in the presence of endogenous expression of adiponectin by adipocytes. The lung tissues of mice implanted with male tumor cells showed elevated wet weights than those implanted with female tumor cells. Moreover, there was a significant difference between the two nude mice groups implanted with male PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) tumor cells, with much higher lung weights in the later group (Table 2). Massive lumps of metastatic tumor mass could be seen on the surface of the lungs from nude mice implanted with male PyVT(+/-)/ADN(+/-) tumor cells. Hematoxylin and eosin staining confirmed that the metastatic capacities of these tumor cells were much higher than those from other groups (Figure 6).
###end p 28
###begin title 29
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Mammary tumor cells derived from adiponectin haplodeficient mice were more aggressive.
###end title 29
###begin p 30
###xml 76 94 76 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 108 126 108 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 220 227 220 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 268 269 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 339 347 339 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 382 400 382 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 405 423 405 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 172 181 <span type="species:ncbi:10090">nude mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
Primary mammary tumor cells were isolated from FVB/N PyVT mice with normal [PyVT(+/-)/ADN(+/+)] or reduced [PyVT(+/-)/ADN(+/-)] adiponectin expressions, and implanted into nude mice for assessing their tumor development in vivo (A and B), or subjected to culture and [3H]-thymidine incorporation assays for evaluating their proliferations in vitro (C and D). The comparison between PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) groups were performed for tumor cells derived from both female (A and C) and male (B and D) mice. Tumor growth was presented as the fold changes of tumor volume against the first measurement at day 4 (A and B). DNA synthesis was monitored in 0.5% and 10% FBS culture conditions at 24 and 48 hrs after seeding (C and D). CPM, counts per minute. *, P<0.05 and **, P<0.01 vs corresponding groups (n = 13-18).
###end p 30
###begin title 31
###xml 30 48 30 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 128 146 128 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 94 103 <span type="species:ncbi:10090">nude mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
Tumor cells derived from male PyVT(+/-)/ADN(+/-) mice show increased metastatic capacities in nude mice comparing with those of PyVT(+/-)/ADN(+/+) mice.
###end title 31
###begin p 32
Both hematoxylin and eosin staining (upper panel) and the morphological evaluations (bottom panel) were performed to evaluate metastasis of the lung tissues.
###end p 32
###begin title 33
###xml 138 156 138 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 161 179 161 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 63 72 <span type="species:ncbi:10090">nude mice</span>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
Total net weights (g) of tumor and lung tissues collected from nude mice implanted with primary tumor cells isolated from female and male PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice.
###end title 33
###begin p 34
###xml 28 46 28 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
p<0.05 vs the corresponding PyVT(+/-)/ADN(+/+) mice group.
###end p 34
###begin p 35
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 127 144 127 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g005">Figure 5, C and D</xref>
###xml 166 184 166 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 398 406 398 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/&#8722;)</italic>
###xml 440 448 440 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADN(+/+)</italic>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
We next compared the proliferation of the isolated primary tumor cells in culture by using [3H]-thymidine incorporation assay (Figure 5, C and D). Cells derived from PyVT(+/-)/ADN(+/-) mice showed dramatically enhanced DNA synthesis under both 0.5% FBS and 10% FBS DMEM culture conditions. Moreover, the fold changes of [3H]-thymidine incorporation between the two time points (24 hr and 48 hr) in ADN(+/-) group were greater than those of ADN(+/+) group. Similar results were also obtained by crystal violet staining and cell number counting (data not shown). These data demonstrated that tumor cells derived from adiponectin haplodeficient mice were more aggressive, and their intrinsic properties were well preserved even under conditions without any hormonal interference.
###end p 35
###begin title 36
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Elevated PI3K/Akt/beta-catenin signalling in tumor cells derived from adiponectin haplodeficient mice
###end title 36
###begin p 37
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 412 421 412 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7A</xref>
###xml 486 504 486 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 718 736 718 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 741 759 741 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1009 1027 997 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/AND(+/&#8722;)</italic>
###xml 1109 1118 1097 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7A</xref>
###xml 1311 1329 1299 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1596 1600 1584 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Chaussade1">[34]</xref>
###xml 1665 1683 1653 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1934 1943 1922 1931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7B</xref>
###xml 2158 2167 2146 2155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7C</xref>
###xml 2281 2300 2269 2288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT (+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 2376 2377 2364 2365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 2639 2648 2627 2636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7D</xref>
###xml 2969 2988 2957 2976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT (+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 3002 3010 2990 2998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g008">Figure 8</xref>
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 2301 2305 <span type="species:ncbi:10090">mice</span>
We previously reported that chronic treatment of adiponectin could modulate GSK3beta/beta-catenin pathway in MDA-MB-231 human breast cancer cells [28]. To investigate whether adiponectin inadequacy could enhance beta-catenin signaling in mammary tumors, we examined the phosphorylation status of GSK3beta and its upstream protein kinase Akt, as well as the protein levels and nuclear activities of beta-catenin (Figure 7A). The results revealed that in primary tumor cells derived from PyVT(+/-)/ADN(+/-) mice, phosphorylations of both Akt at serine 473 and GSK3beta at serine 9 were significantly increased. On the other hand, the phosphorylation of ERK1/2 was not different between the two types of tumor cells from PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice (data not shown). The protein levels of beta-catenin and its target cyclin D1 were largely elevated. The augmented beta-catenin signaling was also confirmed by measuring its nuclear activities, which were increased by approximately4.5 folds in PyVT(+/-)/AND(+/-) tumor cells according to the results from the TOPflash/FOPflash reporter assays (Figure 7A). Inappropriate Akt activation can occur through PI3K. We found that the protein levels of the p110alpha subunits of PI3K, the main isoform involved in oncogenesis, were slightly increased in PyVT(+/-)/ADN(+/-) tumor cells (data not shown). Both general (LY294002) and selective pharmacological antagonists against different isoforms of p110 catalytic subunits (p110alpha-selective inhibitor PIK75, p110beta-selective inhibitor TGX221 and p110delta-selective inhibitor IC8714) [34] were then used for testing their effects in cells isolated from PyVT(+/-)/ADN(+/-) tumors. Treatment with either LY294002 or PIK75 led to significantly attenuated phosphorylations of Akt and GSK3beta and more than 50% reductions of nuclear beta-catenin activities, whereas treatment with IC8714 and TGX221 did not have much impacts (Figure 7B). Similarly, treatment with a specific inhibitor of Akt1 and Akt2 (Akti-1/2) significantly reduced beta-catenin and cyclin-D1 expression levels and caused about 11-fold decrease of nuclear beta-catenin activities (Figure 7C). To further verify the involvement of PI3K and Akt in the accelerated proliferation of tumor cells derived from PyVT (+/-)/ADN(+/-) mice, their inhibitors were used for cell proliferation measurement using [3H]-thymidine incorporation assay. Importantly, the general inhibitor LY294002 and Akti-1/2 showed greater extent of attenuation on the cell growth at all time points, whereas the p110alpha-selective inhibitor PIK75 was more potent than the other two inhibitors (Figure 7D), suggesting that blockade of PI3K or Akt reversed the proliferative advantage of adiponectin haplodeficient tumors. Adiponectin treatment significantly attenuated phosphorylations of Akt and GSK3beta and beta-catenin protein levels and nuclear activities, as well as inhibited cell proliferation to a greater extent in PyVT (+/-)/ADN(+/-) tumor cells (Figure 8). On the other hand, it had little effects on p110alpha levels. These results implicated that the activation of PI3K/Akt pathway might contribute to the elevated beta-catenin signalling cascades in adiponectin haplodeficient mammary tumors.
###end p 37
###begin title 38
Hyperactivation of Akt/GSK3beta/beta-catenin signaling in adiponectin haplodeficient tumors.
###end title 38
###begin p 39
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 326 344 326 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 365 383 365 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 399 400 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 566 584 566 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 623 625 623 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1032 1033 1032 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1069 1087 1069 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1147 1149 1147 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1516 1517 1516 1517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1593 1594 1593 1594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
A, Components of the PI3K/Akt/beta-catenin axis were characterized in the tumor cell lysates by Western blotting (upper panel) and nuclear beta-catenin activities analyzed using a TOPflash/FOPflash luciferase reporter assay (bottom panel). Results were expressed as fold changes relative to the values of samples derived from PyVT(+/-)/ADN(+/+) cells. #, P<0.01 vs PyVT(+/-)/ADN(+/+) group (n = 6). B, Various pharmacological inhibitors, including LY294002 for PI3K, PIK-75 for p110alpha, TGX221 for p110beta and IC8714 for p110delta, were used for the treatment of PyVT(+/-)/ADN(+/-) tumor cells at the concentration of 10-6 M. The phosphorylations of Akt (pAkt), GSK3beta (pGSK3beta), and beta-catenin (pBeta-catenin), as well as their total levels in the cell samples treated with each specific inhibitor for 30 min were analyzed by Western Blotting (upper panel). After 24 hr incubation, the nuclear beta-catenin activities were evaluated using the TOPflash/FOPflash reporter assay (bottom panel). *, P<0.01 vs vehicle (n = 4). C, Primary tumor cells isolated from PyVT(+/-)/ADN(+/-) mice were cultured and treated without (vehicle) or with 10-6 M of specific inhibitor of Akt-1/Akt-2 isoforms (Akti-1/2) for 24 hr. Protein levels of phosphorylated Akt (pAkt), beta-catenin, and cyclinD1 in the cell lysates were analyzed by Western Blotting (upper panel) and the nuclear beta-catenin activities measured using a TOPflash/FOPflash luciferase reporter system (bottom panel). *, P<0.01 vs vehicle control (n = 3). D, Evaluation of the effects of various inhibitors on cell proliferation by [3H]-thymidine incorporation assay. CPM, counts per minute. *, P<0.01 vs vehicle in each treatment group (n = 5). Results were derived from three independent experiments.
###end p 39
###begin title 40
###xml 25 43 25 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Tumor cells derived from PyVT(+/-)/ADN(+/-) mice showed increased sensitivity to adiponectin-mediated inhibition of Akt/GSK3beta/beta-catenin signaling and cell proliferation.
###end title 40
###begin p 41
###xml 31 49 31 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 54 72 54 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 297 301 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 510 511 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Tumor cells isolated from both PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice were pre-treated with 15 microg/ml of adiponectin for 24 hr in 0.5% FBS DMEM. The serum-stimulated phosphorylation changes of Akt, GSK3beta and beta-catenin were analyzed by Western Blotting (A) as described previously [28]. The nuclear beta-catenin activities were assayed using the TOPflash/FOPflash reporter assay (B). Cell proliferation was evaluated for both types of tumor cells under the indicated treatment conditions using 3H-thymidine incorporation assay (C). *, P<0.05 and **, P<0.01 vs corresponding vehicle control (n = 3, from three independent experiments).
###end p 41
###begin title 42
Decreased PTEN activities caused by altered redox environment in adiponectin haplodeficient PyVT tumors
###end title 42
###begin p 43
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Carnero1">[44]</xref>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Meuillet1">[45]</xref>
###xml 443 462 443 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT (+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 476 485 476 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9A</xref>
###xml 554 563 554 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9B</xref>
###xml 666 684 666 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 698 707 698 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9A</xref>
###xml 764 782 764 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 787 805 787 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 857 875 857 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 889 898 889 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g008">Figure 8B</xref>
###xml 1081 1090 1081 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)</italic>
###xml 1097 1106 1097 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9C</xref>
###xml 1219 1237 1219 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1325 1334 1325 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9A</xref>
###xml 1428 1437 1428 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9A</xref>
###xml 1443 1461 1443 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1479 1484 1479 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TrxR1</italic>
###xml 1565 1583 1553 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1597 1606 1585 1594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9D</xref>
###xml 1716 1734 1692 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1781 1799 1757 1775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1852 1857 1828 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TrxR1</italic>
###xml 1922 1931 1898 1907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9D</xref>
###xml 1091 1095 <span type="species:ncbi:10090">mice</span>
###xml 2034 2038 <span type="species:ncbi:10090">mice</span>
PTEN is one of the most frequently mutated tumor suppressors that can prevent the activation of the cell survival PI3K/Akt signaling pathway [44]. In the absence of PTEN function, cells exhibit elevated Akt activities. It has been reported that PTEN could bind to Trx1 in the cytosol, resulting in a functional loss of its lipid phosphatase and membrane binding activity [45]. Interestingly, PTEN activities were decreased by more than 50% in PyVT (+/-)/ADN(+/-) tumor cells (Figure 9A), whereas its total protein amount was not significantly different (Figure 9B). The activities of both Trx1 and its upstream binding enzyme, TrxR1, were augmented by nearly 40% in PyVT(+/-)/ADN(+/-) tumor cells (Figure 9A). While the protein levels of Trx1 were similar between PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) tumors, the total amount of TrxR1 was increased in PyVT(+/-)/ADN(+/-) tumor cells (Figure 8B). Surprisingly, co-immunoprecipitation experiment revealed that the amounts of Trx1-bound PTEN were dramatically increased in tumor cells derived from the adiponectin haplodeficient PyVT(+/-) mice (Figure 9C). Treatment with curcumin, an irreversible inhibitor of TrxR1 (40), elevated PTEN activity by nearly 3 folds in PyVT(+/-)/ADN(+/-) tumor cells, which was accompanied by the decreased activities of both TrxR1 and Trx1 (Figure 9A). A stimulatory effect on PTEN activity was also observed in cells treated with adiponectin (Figure 9A). In PyVT(+/-)/ADN(+/-) tumor cells, the TrxR1 promoter-driven reporter activity was approximately1.8 fold higher than that of PyVT(+/-)/ADN(+/+) tumor cells (Figure 9D). Treatment with adiponectin for 24 hrs significantly reduced the reporter activities by approximately60% in PyVT(+/-)/ADN(+/-) tumor cells but had no significant effects on PyVT(+/-)/ADN(+/+) tumor cells. Similar effects were also observed for TrxR1 mRNA levels in tumor cells treated with or without adiponectin (Figure 9D). Taken together, these results suggested that in tumor cells derived from adiponectin haplodeficient mice, the increased TrxR1/Trx1 redox activities might be involved in inactivation of PTEN and hyperactivation of PI3K/Akt signalling pathways.
###end p 43
###begin title 44
###xml 99 117 99 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
Inactivation of PTEN was at least partially caused by the augmented Trx1/TrxR1 redox activities in PyVT(+/-)/ADN(+/-) tumor cells.
###end title 44
###begin p 45
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 80 98 80 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 103 121 103 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 361 368 353 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 446 464 438 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 507 508 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 576 594 568 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 599 617 591 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 660 661 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 760 778 752 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 783 801 775 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 921 922 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1062 1080 1054 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1085 1103 1077 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1283 1301 1271 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 1329 1347 1317 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
A, activities of PTEN, TrxR1 and Trx were evaluated in the lysates derived from PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) tumor cells using colorimetric assays. Briefly, cells were treated with vehicle control (CON), 10 microM curcumin (CUR) or 15 microg/ml adiponectin (ADN) for 24 hrs. Immunoprecipitation and phosphatase assay were performed as described in Methods. Results were expressed as fold changes relative to the enzyme activities in PyVT(+/-)/ADN(+/+) tumor cells treated with vehicle control. B, total protein levels of PTEN, TrxR1 and Trx1 in cell lysates from PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) tumors were analyzed by Western Blotting. C, co-immunoprecipitations were performed with the specific antibodies against PTEN or Trx1 in both PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) tumor cell lysates. The immune-complexes were analyzed by SDS-PAGE and Western Blotting using antibodies as indicated. D, intrinsic transcriptional activities of TrxR1 promoter (left panel) and the mRNA levels of TrxR1 and Trx1 (right panel) were evaluated in PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) tumor cells treated without (CON) or with adiponectin (ADN, 15 microg/ml) using TrxR1 reporter assay (left panel) and quantitative RT-PCR respectively (right panel). *, P<0.05 vs PyVT(+/-)/ADN(+/+) cell control; #, P<0.05 vs PyVT(+/-)/ADN(+/-) cell control (n = 3, from three independent experiments).
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 458 466 458 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g002">Figure 2</xref>
###xml 468 476 468 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g003">Figure 3</xref>
###xml 481 488 481 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004968-t001">Table 1</xref>
###xml 545 563 545 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 670 678 670 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g005">Figure 5</xref>
###xml 1007 1025 1007 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1032 1040 1032 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g004">Figure 4</xref>
###xml 1246 1254 1246 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7</xref>
###xml 1415 1423 1415 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g008">Figure 8</xref>
###xml 1553 1571 1553 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1580 1588 1580 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9</xref>
###xml 273 277 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 619 628 <span type="species:ncbi:10090">nude mice</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1095 1099 <span type="species:ncbi:10090">mice</span>
Although the anti-tumor activities of adiponectin have been suggested by numerous clinical and experimental evidences, the underlying mechanisms remain to be established. Here, we have evaluated the impacts of reduced adiponectin expression on mammary tumor development in MMTV-PyVT mice. Our results demonstrate that in both FVB/N and C57BL/6J genetic backgrounds, adiponectin inadequacy is associated with earlier tumor onset and accelerated tumor growth (Figure 2, Figure 3 and Table 1). The aggressive phenotypes of tumor cells derived from PyVT(+/-)/ADN(+/-) mice are retained during serial trans-implantations in nude mice as well as multiple passages in culture (Figure 5), suggesting that insufficient adiponectin production from adipose tissue might result in an abnormal microenvironment that leads to distinct but permanent genetic and phenotypic modifications of mammary epithelial cells. Indeed, both histological and gene expression analyses suggest a distinct basal-like subtype of tumors in PyVT(+/-)/ADN(+/-) mice (Figure 4). Tumor cells derived from adiponectin haplodeficient mice show enhanced beta-catenin nuclear activities and protein stabilities, which might be partly attributed to the hyperactivated PI3K/Akt signaling (Figure 7). While adiponectin treatment restores most of the changes downstream of PI3K, including Akt and GSK3beta and beta-catenin, it has little effects on p110alpha (Figure 8). On the other hand, adiponectin deficiency causes inactivation of PTEN and results in the hyper-activated PI3K/Akt signaling in PyVT(+/-)/ADN(+/-) tumors (Figure 9).
###end p 47
###begin p 48
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Dillon1">[46]</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Tamguney1">[47]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Carnero1">[44]</xref>
###xml 680 688 680 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9</xref>
###xml 782 786 782 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Leslie1">[48]</xref>
###xml 1100 1104 1100 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Arnr1">[49]</xref>
###xml 1333 1337 1333 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Meuillet1">[45]</xref>
###xml 1523 1527 1523 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Hui1">[50]</xref>
###xml 1728 1737 1728 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9A</xref>
###xml 1898 1907 1898 1907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g009">Figure 9D</xref>
###xml 2106 2124 2106 2124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 317 322 <span type="species:ncbi:9606">human</span>
###xml 1670 1674 <span type="species:ncbi:10090">mice</span>
###xml 2125 2129 <span type="species:ncbi:10090">mice</span>
PTEN/PI3K/Akt constitutes an important pathway regulating the signaling of multiple biological processes such as apoptosis, metabolism and cell proliferation [46]. PTEN activity is lost by mutations, deletions, promoter methylation silencing, or protein modifications at high frequency in many primary and metastatic human cancers [47]. Hyperactivation of the PI3K/Akt signaling pathway triggered by PTEN inactivation has been found to correlate with increased breast cancer risks, poor prognosis and resistance to hormone therapy [44]. In adiponectin haplodeficient PyVT tumors, while the total protein levels of PTEN are not altered, its activities are significantly decreased (Figure 9). PTEN is well-known to be regulated by the redox state of the active site cysteine residues [48]. Oxidation of PTEN resulted from thiol modification leads to reversible inhibition of its phosphatase activity. The thioredoxin system, composed of TrxR, Trx, and NADPH, represents one of the main thiol-dependent electron donor systems and plays critical roles in the regulation of the cellular redox environment [49]. Although the reduction of oxidized PTEN appears to be dominantly mediated by Trx, it has been reported that Trx1 inhibits its phosphatase activity by binding in a redox dependent manner to PTEN through disulfide bond formation [45]. Moreover, knocking out of thioredoxin-interacting protein, an inhibitor of Trx NADPH-dependent reduction of PTEN, causes accumulation of oxidized PTEN and elevated Akt phosphorylation [50]. We find that there is a significantly augmented formation of Trx1-PTEN complexes in tumor cells derived from adiponectin haplodeficient PyVT mice, possibly due to elevated TrxR1 and Trx1 activities (Figure 9A). Adiponectin treatment decreases TrxR1 promoter-mediated transcription and its mRNA levels, which are highly upregulated in adiponectin haplodeficient tumors (Figure 9D). These results suggest that adiponectin might regulate PTEN activities through Trx/TrxR redox system, and an altered Trx/TrxR redox balance could play important roles in promoting tumorigenesis in PyVT(+/-)/ADN(+/-) mice.
###end p 48
###begin p 49
###xml 293 301 293 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Zhao1">[51]</xref>
###xml 703 707 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Kim1">[52]</xref>
###xml 844 848 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Tureckov1">[53]</xref>
###xml 1059 1063 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Naito1">[54]</xref>
###xml 1331 1339 1331 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g007">Figure 7</xref>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 1180 1184 <span type="species:ncbi:10090">mice</span>
In this study, we have shown that inhibition of both PI3K and Akt results in a reduced nuclear beta-catenin activities and protein stabilities, supporting the involvement of PI3K/Akt pathway in the hyper-activation of beta-catenin signalling associated with adiponectin haplodeficient tumors (Figure 7). Notably, the cross-talks between PI3K/Akt and the canonical Wnt/beta-catenin signaling pathways have been demonstrated by a number of studies from independent groups (23). Overexpression of PTEN inhibits Wnt-1 induced beta-catenin stabilization and mammary tumorigenesis in mice [51]. PI3K/Akt pathway is involved in Wnt3a-induced proliferation and beta-catenin nuclear accumulation in NIH3T3 cells [52]. In HT29 colorectal adenocarcinoma cells, inhibition of PI3K was accompanied by a considerably reduced expression level of beta-catenin [53]. The linkage between Wnts and PI3K/Akt signalling have also been found in the regulation of bone mass, osteoblast progenitor proliferation, differentiation and osteoblast apoptosis, as well as cardiomyogenesis [54]. The protein levels of p110alpha subunits are elevated in tumor cells isolated from adiponectin haplodeficient PyVT mice. However, adiponectin treatment has no effects on p110alpha, despite that it can inhibit Akt phosphorylation and nuclear beta-catenin activities (Figure 7), suggesting that the inhibitory effects of this hormone is downstream of PI3K and upstream of Akt, possibly through modulating PTEN's activities.
###end p 49
###begin p 50
###xml 212 230 212 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 235 253 235 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 260 268 260 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004968-g003">Figure 3</xref>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Livasy1">[43]</xref>
###xml 1322 1326 1322 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Zhou1">[55]</xref>
###xml 1429 1433 1429 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Liu1">[56]</xref>
###xml 1512 1516 1512 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Bloomfield1">[57]</xref>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
Insufficiency in adiponectin production might promote mammary tumor formation from distinct type of cells, as suggested by the consistent morphological and gene expression differences between tumors derived from PyVT(+/-)/ADN(+/+) and PyVT(+/-)/ADN(+/-) mice (Figure 3). Adiponectin haplodeficient tumor is more related to a basal-like subtype, which is characterized by high proliferative activity and unfavorable prognosis. The origin of this subtype tumor is unclear, but suggested to be the basal/myoepithelial cells, derived from epithelial-to-mesenchymal transition as a result of dedifferentiation, or from stem cells [43]. It will be interesting to investigate which types of tumor cell transformation could be facilitated by the altered microenvironment associated with adiponectin haploinsufficiency. It has long been noticed that cancer cells exhibit increased glycolysis for ATP production due, in part, to respiration injury (the Warburg effect). The increase in NADH caused by respiratory deficiency inactivates PTEN through a redox modification mechanism, leading to Akt activation. Our group has recently reported that adiponectin deficiency leads to dysregulated mitochondrial functions, which result in decreased activities of the respiratory chain and subsequent accumulation of reactive oxygen species [55]. We have also found that adiponectin can modulate redox-regulated transcription factor Sp1 activities [56]. Interestingly, the expression of both Trx1 and TrxR1 can be regulated by Sp1 [57]. Whether these mechanisms contribute to the dysregulated Trx/TrxR redox system in adiponectin insufficiency-related carcinogenesis are currently under investigation in our laboratory. Nevertheless, these findings might provide a novel mechanistic insight to explain how metabolic alteration in adiponectin haplodeficient tumor may gain a survival advantage.
###end p 50
###begin title 51
Materials and Methods
###end title 51
###begin title 52
Materials
###end title 52
###begin p 53
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Chaussade1">[34]</xref>
###xml 829 833 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-DeFeoJones1">[35]</xref>
###xml 1437 1441 1428 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Tamura1">[36]</xref>
###xml 1665 1669 1656 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 559 564 <span type="species:ncbi:9940">sheep</span>
###xml 1235 1240 <span type="species:ncbi:9606">human</span>
###xml 1314 1319 <span type="species:ncbi:9606">human</span>
###xml 1366 1369 <span type="species:ncbi:10116">rat</span>
###xml 1394 1397 <span type="species:ncbi:10116">rat</span>
Antibodies against PI3K p110-alpha (#4255), PI3K p85 (#4292), phospho-Akt (Ser473) (#9271), Akt (#9272), GSK3beta (#9315), phospho-GSK3beta (Ser9) (#9336) and phospho-beta-catenin (Ser33/37/Thr41) (#9561) were obtained from Cell Signaling Biotechnology (Beverly, MA). Anti-Trx1 (sc-20146), anti-TrxR1 (sc-28321), and anti-beta actin (sc-1615) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-PTEN (MAB4037) was from Chemicon International, Inc. (Temecula, CA), anti-Cyclin D1 (CC12) was from CalBiochem-Novachem Crop. (San Diego, CA), and sheep anti-beta-catenin was from Symansis (Auckland, New Zealand). Pharmacological inhibitors, including Akt-1/2 inhibitor, PI3K p110alpha inhibitor PIK-75, PI3K p110beta inhibitor TGX221, and PI3K p110delta inhibitor IC87114 were provided by Dr Peter R. Shepherd [34], [35]. The general PI3K inhibitor, LY294002, was from Cell Signaling Biotechnology. ImProm-IItrade mark Reverse Transcription System and Bright-GloTM luciferase assay system were from Promega (Madison, WI). TOP/FOPflash (T-cell factor-lymphoid enhancer factor-1 (TCF-LEF) reporter plasmid) was from Upstate (Lake Plasid, NY). pGL-TrxR1 reporter plasmid was generated by cloning the proximal promoter of the human TrxR1 gene using the GenomeWalker kit from Clontech (Palo Alto, CA). The human TrxR1 and Trx1 were purchased from Sigma. The rat TrxR1 was purified from rat liver according to published procedure [36] and the purity confirmed by mass spectrometry analysis. Unless specified, all chemicals were obtained from Sigma-Aldrich Co. (St Louis, MO). Recombinant full length adiponectin (ADN) was produced as we described previously [28].
###end p 53
###begin title 54
###xml 21 25 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 31 46 <span type="species:ncbi:10090">transgenic mice</span>
Establishment of the MMTV-PyVT transgenic mice haplodeficient in adiponectin expression
###end title 54
###begin p 55
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Guy1">[37]</xref>
###xml 285 294 285 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)</italic>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Ma1">[38]</xref>
###xml 582 589 582 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004968-t003">Table 3</xref>
###xml 793 811 793 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(&#8722;/&#8722;)</italic>
###xml 1306 1324 1306 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1391 1409 1391 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/&#8722;)</italic>
###xml 1502 1520 1494 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PyVT(+/&#8722;)/ADN(+/+)</italic>
###xml 2037 2038 2021 2022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2063 2064 2047 2048 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 9 13 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 28 43 <span type="species:ncbi:10090">transgenic mice</span>
###xml 134 149 <span type="species:ncbi:10090">transgenic mice</span>
###xml 246 261 <span type="species:ncbi:10090">transgenic mice</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
###xml 1234 1249 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1429 1433 <span type="species:ncbi:10090">mice</span>
###xml 1521 1525 <span type="species:ncbi:10090">mice</span>
###xml 1797 1801 <span type="species:ncbi:10090">mice</span>
FVB/N-Tg(MMTV-PyVT)634Mul/J transgenic mice were obtained from the Jackson Laboratory (Bar Harbor, Maine) [37]. Since the female PyVT transgenic mice were defective in litter delivery and lactation, all breedings were carried out using male PyVT transgenic mice. The male heterozygote PyVT(+/-) mice were cross-bred with female adiponectin knockout mice [38] and back-crossed for at least 12 generations to obtain mice with reduced adiponectin expression in both C57BL/6J and FVB/N backgrounds. The genotype was verified by PCR analysis of their genomic DNA using primers listed in Table 3. In addition, serum adiponectin levels were monitored using an in-house ELISA, with the standard curve generated from known concentrations of recombinant adiponectin. Note that mice with the genotype of PyVT(+/-)/ADN(-/-) (transgenic PyVT with adiponectin null alleles) could not be found in all generations of alive litters, which included over 800 mice. On the other hand, their embryos were found to be dead at the early stage of foetal development. As a consequence, the sizes of litters with abnormal adiponectin expressions (3-5) were consistently smaller when compared to those of control PyVT breeding pairs (8-10). Therefore, the PyVT transgenic mice with adiponectin deficiency were referred to those with PyVT(+/-)/ADN(+/-) genotypes in this study. The circulating levels of adiponectin in PyVT(+/-)/ADN(+/-) FVB/N and C57BL/6J mice range from 3-15 microg/ml and 0.2-5 microg/ml respectively, whereas PyVT(+/-)/ADN(+/+) mice in both FVB/N and C57BL/6J background have a much higher adiponectin level of over 20 microg/ml and 10 microg/ml respectively, with the median values increased by 4-5 folds. Tumor development was closely monitored every 2-3 days. Tumor latency was recorded as the age of mice when palpable tumors were first detected in at least one of the ten mammary fat pads. Tumor sizes were measured using digital vernier calipers and tumor volume calculated using the formula [sagittal dimension (mm)x(cross dimension (mm)2] / 2 and expressed in mm3. All animal experimental protocols were approved by the Animal Ethics Committee at the University of Hong Kong and their care was in accord with the institution guidelines.
###end p 55
###begin title 56
List of primers used for genotyping.
###end title 56
###begin title 57
###xml 19 25 <span type="species:ncbi:10090">murine</span>
Sandwich ELISA for murine adiponectin
###end title 57
###begin p 58
###xml 975 976 939 940 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 978 979 942 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 9 15 <span type="species:ncbi:10090">murine</span>
###xml 150 156 <span type="species:ncbi:10090">murine</span>
###xml 365 371 <span type="species:ncbi:9913">bovine</span>
###xml 435 441 <span type="species:ncbi:9913">bovine</span>
###xml 481 486 <span type="species:ncbi:10090">Mouse</span>
###xml 851 862 <span type="species:ncbi:3704">horseradish</span>
The anti-murine adiponectin monoclonal antibody was biotinylated with a kit from Pierce, and free biotin was removed by dialysis. The polyclonal anti-murine adiponectin antibody was diluted to a concentration of 2 microg/ml, added to each well of a microtiter plate, and incubated overnight at 4 degreesC. The coated plate was washed 3 times with PBS containing 1% bovine serum albumin and blocked with 100 microl of PBS containing 1% bovine serum albumin and 0.05% Tween for 2 h. Mouse serum was diluted 1:10000, and 100 microl of the diluted samples were applied to each well along with the standard, incubated at 37 degreesC for 1 h, washed 3 times with PBS-Tween, and then incubated with 100 microl of the biotinylated monoclonal antibody (2 microg/ml) for another 2 h. After washing 3 times, the wells were incubated with streptavidin-conjugated horseradish peroxidase for 60 min and subsequently reacted with tetramethylbenzidine reagent for 15 min. 100 microl of 2 M H2SO4 was added to each well to stop the reaction, and the absorbance at 450 nm was measured. The intra- and interassay coefficients of variance were determined by measuring five plasma samples in a total of six independent assays with duplicate determinations.
###end p 58
###begin title 59
Primary tumor cell isolation, culture and re-implantation
###end title 59
###begin p 60
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Varticovski1">[39]</xref>
###xml 584 585 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 694 698 <span type="species:ncbi:10090">mice</span>
Primary cell isolation was performed as described previously with slight modifications [39]. Briefly, aseptically collected tumors from PyVT mice were mechanically minced, passaged through a 100-microm sterile nylon cell strainer (BD Falcon) and suspended in serum-free high glucose DMEM. Cells were further dissociated by serial passaging through a syringe with 25-gauge needles. After brief centrifugation at 1,000 r.p.m for 5 minutes to remove dead cell debris and the low-density stromal cells, the cell pellets were resuspended for viable cell counting using 0.4% trypan blue. 106 of isolated primary tumor cells were implanted into the third right mammary fat pad of female athymic nu/nu mice (4-6 weeks) by intraductal injection. Tumor development was monitored every 3-4 days using caliper measurements (in millimeters) in two perpendicular dimensions (length and width). Tumor volumes were calculated as described above.
###end p 60
###begin title 61
Co-immunoprecipitation and Western Blotting
###end title 61
###begin p 62
###xml 553 559 <span type="species:ncbi:9986">rabbit</span>
Isolated tumor tissues were homogenized in RIPA buffer [50 mM Tris-HCl, pH 7.4; 1 mM EDTA; 150 mM NaCl; 1% Nonidel P40; 1% Triton X-100; 0.5% deoxycholic acid sodium salt; 1 mM NaF; 1 mM sodium orthovanadate; and complete protease inhibitor cocktail (Roche Applied Science, IN)] on ice and centrifuged for 5 min at 14,000 r.p.m to remove large debris. Protein concentration of the supernatant was determined by a BCA Protein Reagent Kit (Pierce Biotechnology, Rockford, IL). Five hundred micrograms of the total cell lysates were firstly incubated with rabbit IgG for 30 minutes, pre-cleared with 50 microl of protein G-Sepharose beads (Pierce Biotechnology, Rockford, IL), and then incubated with two micrograms of either Anti-Trx1 or Anti-PTEN antibody overnight at 4degreesC. 50 microl of protein G-Sepharose beads was added and incubated for 2 hrs at 4degreesC. Beads bound with immune complexes were collected by centrifugation and washed twice prior to elution into 90 microl of buffer containing 0.2 M Glycine-HCl, pH 2.5, which was neutralized with 10 microl of neutralization buffer (1 M Tris-HCl, pH 9.0). The elutants were subjected to 15% SDS-PAGE and Western blotting analysis, or enzyme activity measurement as described below.
###end p 62
###begin p 63
For Western Blotting, fifty micrograms of proteins derived from cell or tissue lysates were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. Following blocking, membranes were probed with various primary antibodies to determine different levels of protein expressions. Immunoreactive antibody-antigen complexes were visualized with the enhanced chemiluminescence reagents from GE Healthcare (Uppsala, Sweden).
###end p 63
###begin title 64
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
[3H]-thymidine incorporation assay for cell proliferation measurement
###end title 64
###begin p 65
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 232 233 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 583 584 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
5x104 of isolated primary tumor cells were seeded into each of the 24-well culture plate and allowed a period of at least 24 hours for cell settlement and attachment. After being treated under different conditions, 1 microCi/ml of [3H-methyl] thymidine was added into each well for 6 hours of incorporation. At the end of experiment, the culture media were removed and cells washed twice with cold PBS. DNA was precipitated with 0.5% trichloroacetic acid for 30 min. Air-dried precipitates were then solubilized with 0.2 mol/l NaOH, neutralized with 0.2 mol/l HCl, and incorporated [3H]-thymidine was quantified with a liquid scintillation counter (Backman LS6500).
###end p 65
###begin title 66
Quantitative RT-PCR
###end title 66
###begin p 67
###xml 424 431 413 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004968-t004">Table 4</xref>
Total RNA was isolated from primary tumor cells and used for the synthesis of cDNA. Quantitative RT-PCR was performed using SYBR(R) GreenERtrade mark qPCR Supermix (Invitrogen, Carlsbad, CA). The reactions were carried out on a 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). Quantification was achieved using Ct values that were normalized with 18S RNA as internal control. The primers were listed in Table 4.
###end p 67
###begin title 68
List of primers used for real time quantitative PCR analysis.
###end title 68
###begin title 69
Beta-catenin/T-cell factor-lymphoid enhancer factor-1 (TCF-LEF) and thioredoxin reductase 1 (TrxR1) transcription reporter assay
###end title 69
###begin p 70
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Wang3">[28]</xref>
###xml 266 273 266 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 844 851 835 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 421 426 <span type="species:ncbi:9606">human</span>
Nuclear activities of endogenous beta-catenin were analyzed by the TOPflash/FOPflash reporter system as described previously [28]. To normalize transfection efficiency in the reporter assays, cells were cotransfected with pRL-TK plasmid, which contains a functional Renilla luciferase gene cloned downstream of a herpes simplex virus thymidine kinase promoter (Promega, Madison, WI). The luciferase reporter containing a human thioredoxin reductase promoter region (from -386 bp to +218 bp, pGL3-TR) was constructed into a firefly-luciferase pGL3-basic Vector (Promega, Madison, WI). The assay was carried out as described above with the original unmodified pGL3-basic vector as a negative control. Luminescence was measured using a Bright-Glotrade mark Luciferase Assay System (Promega, Madison, WI) on Lumat LB9507, and normalized to control Renilla luciferase signal. Luciferase activity was calculated against the negative control signals and fold differences were compared among groups in separate assays.
###end p 70
###begin title 71
Measurement of PTEN lipid phosphatase activities
###end title 71
###begin p 72
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Georgescu1">[40]</xref>
###xml 473 474 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The lipid phosphatase activity of PTEN was measured as described previously with slight modifications [40]. Phosphatase reactions were performed in 25 microl assay buffer (100 mM Tris-HCl pH 8, 10 mM DTT, and 200 microM water-soluble diC8-PIP3) with 25 microl sample. PTEN proteins immunoprecipitated on protein G-Sepharose beads (Pierce Biotechnology, Rockford, IL) were washed twice in a low stringency buffer (20 mM HEPES, pH 7.7, 50 mM NaCl, 0.1 mM EDTA and 2.5 mM MgCl2) and once in the phosphatase assay buffer lacking PIP3. Reactions were done in a 96-well plate with an incubation period of 40 minutes at 37degreesC. The release of phosphate from the substrate was measured in a colorimetric assay by using the Biomol Green Reagent in accordance with the instructions of the manufacturer. The absorbance at 620 nm was measured with a microQuant MQX200 microplate reader (Biotek Instruments, Inc., Highland Park, VT). A standard curve was performed in each assay, and the amount of free phosphate was calculated from the standard curve line-fit data.
###end p 72
###begin title 73
Measurement of TrxR1 and Trx1 activities
###end title 73
###begin p 74
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004968-Lu1">[41]</xref>
###xml 975 977 949 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 980 982 954 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 403 408 <span type="species:ncbi:9606">human</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
###xml 1104 1107 <span type="species:ncbi:10116">rat</span>
The assays for measuring the activities of TrxR and Trx were performed in 96-well plates using an insulin reduction endpoint assay as described previously [41] with slight modification. For determination of TrxR1 activity, 25 microg of the primary tumor lysates were mixed thoroughly with a 50 microl reaction buffer containing 55 mM HEPES, pH 7.6, 0.02 mM insulin, 0.4 mM NADPH, 2 mM EDTA and 2 microM human Trx1 in the microQuant MQX200 microplate reader (Biotek Instruments, Inc). Reaction solutions without human Trx1 were used as the control. After performing a 20-min incubation at 37degreesC, 200 microl of 1 mM DTNB in 6 M guanidine hydrochloride solution was added to stop the reaction. The free thiols of the reduced insulin were determined by DTNB reduction, and the activity of TrxR was represented as the absorbance at wavelength 412 nm, where 1 mole of NADPH reduced 1 mole of disulfide, giving rise to 2 mole of free TNB with the extinction coefficient 13.6 mM-1 cm-1. For accessing the activity of Trx, assays were performed as above with the similar reaction cocktail except that 600 nM rat TrxR1 but not Trx1 was included. Reaction solutions without TrxR1 were used as the control.
###end p 74
###begin title 75
Data analysis and statistics
###end title 75
###begin p 76
###xml 466 473 464 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 478 486 476 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
All experiments were performed with six to eight samples per group, and all results were derived from at least three independent experiments. Data are shown as mean values +/-standard deviation (SD). Comparison between groups was done using Student's unpaired t-test. Tumor latency was analysed using a Kaplan-Meier survival analysis followed by log rank tests. In all statistical comparisons, P<0.05 was used to indicate a significant difference. Note that for the ex vivo and in vitro experiments, while tumor cells derived from male and female mice showed similar characteristics in both FVB/N and C57BL/6J backgrounds, only results derived from the tumor cells of female FVB/N mice were shown.
###end p 76
###begin p 77
###xml 121 125 <span type="species:ncbi:10090">mice</span>
We thank Dr Keith Leung and Prof. Kathy Cheah for helping with the embryo re-derivation experiment. Adiponectin knockout mice were kindly provided by Dr. Lawrence Chan at Baylor College of Medicine.
###end p 77
###begin title 78
References
###end title 78
###begin article-title 79
Obesity and cancer.
###end article-title 79
###begin article-title 80
Obesity and cancer: the risks, science, and potential management strategies.
###end article-title 80
###begin article-title 81
Medical consequences of obesity.
###end article-title 81
###begin article-title 82
Adipocytokines and cancer.
###end article-title 82
###begin article-title 83
Obesity, adipokines, and prostate cancer (review).
###end article-title 83
###begin article-title 84
[Hormones of adipose tissue (adipocytokines): ontogenetic and oncologic aspects].
###end article-title 84
###begin article-title 85
Obesity, adipocytokines, and insulin resistance in breast cancer.
###end article-title 85
###begin article-title 86
Post-translational modifications of adiponectin: mechanisms and functional implications.
###end article-title 86
###begin article-title 87
Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.
###end article-title 87
###begin article-title 88
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.
###end article-title 88
###begin article-title 89
Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer.
###end article-title 89
###begin article-title 90
Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression.
###end article-title 90
###begin article-title 91
Adiponectin as a negative regulator in obesity-related mammary carcinogenesis.
###end article-title 91
###begin article-title 92
Obesity and prostate cancer: a role for adipokines.
###end article-title 92
###begin article-title 93
Adiponectin and cancer: a systematic review.
###end article-title 93
###begin article-title 94
Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come.
###end article-title 94
###begin article-title 95
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.
###end article-title 95
###begin article-title 96
Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.
###end article-title 96
###begin article-title 97
Adiponectin and breast cancer risk.
###end article-title 97
###begin article-title 98
Anthropometric measures, plasma adiponectin, and breast cancer risk.
###end article-title 98
###begin article-title 99
Plasma adiponectin concentrations and risk of incident breast cancer.
###end article-title 99
###begin article-title 100
Association of serum adiponectin levels with breast cancer risk.
###end article-title 100
###begin article-title 101
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Serum adiponectin and leptin levels in Taiwanese breast cancer patients.
###end article-title 101
###begin article-title 102
Relationship of serum adiponectin and resistin levels with breast cancer risk.
###end article-title 102
###begin article-title 103
###xml 23 28 <span type="species:ncbi:9606">human</span>
Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol.
###end article-title 103
###begin article-title 104
Effects of adiponectin on breast cancer cell growth and signaling.
###end article-title 104
###begin article-title 105
Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer.
###end article-title 105
###begin article-title 106
###xml 148 157 <span type="species:ncbi:10090">nude mice</span>
Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.
###end article-title 106
###begin article-title 107
###xml 66 71 <span type="species:ncbi:9606">human</span>
Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells.
###end article-title 107
###begin article-title 108
Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell.
###end article-title 108
###begin article-title 109
###xml 70 75 <span type="species:ncbi:9606">human</span>
Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis.
###end article-title 109
###begin article-title 110
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model.
###end article-title 110
###begin article-title 111
Antagonistic proliferative activities of adiponectin and leptin in breast cancer: study on MCF7 cells.
###end article-title 111
###begin article-title 112
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
###end article-title 112
###begin article-title 113
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.
###end article-title 113
###begin article-title 114
Mammalian thioredoxin reductases.
###end article-title 114
###begin article-title 115
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
###end article-title 115
###begin article-title 116
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin.
###end article-title 116
###begin article-title 117
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
###end article-title 117
###begin article-title 118
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.
###end article-title 118
###begin article-title 119
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
###end article-title 119
###begin article-title 120
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
###end article-title 120
###begin article-title 121
Identification of a basal-like subtype of breast ductal carcinoma in situ.
###end article-title 121
###begin article-title 122
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
###end article-title 122
###begin article-title 123
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
###end article-title 123
###begin article-title 124
###xml 71 76 <span type="species:ncbi:9606">human</span>
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.
###end article-title 124
###begin article-title 125
New insights into PTEN.
###end article-title 125
###begin article-title 126
PTEN function: how normal cells control it and tumour cells lose it.
###end article-title 126
###begin article-title 127
Physiological functions of thioredoxin and thioredoxin reductase.
###end article-title 127
###begin article-title 128
Txnip balances metabolic and growth signaling via PTEN disulfide reduction.
###end article-title 128
###begin article-title 129
Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis.
###end article-title 129
###begin article-title 130
The PI3 kinase-Akt pathway mediates Wnt3a-induced proliferation.
###end article-title 130
###begin article-title 131
Expression of beta-catenin is regulated by PI-3 kinase and sodium butyrate in colorectal cancer cells.
###end article-title 131
###begin article-title 132
Phosphatidylinositol 3-kinase-Akt pathway plays a critical role in early cardiomyogenesis by regulating canonical Wnt signaling.
###end article-title 132
###begin article-title 133
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury.
###end article-title 133
###begin article-title 134
Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1.
###end article-title 134
###begin article-title 135
Thioredoxin-mediated redox control of the transcription factor Sp1 and regulation of the thioredoxin gene promoter.
###end article-title 135
###begin p 136
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 136
###begin p 137
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
Funding: This work was supported by the grants from Seeding Funds for Basic Research of the University of Hong Kong (Y. Wang), Hong Kong Research Grant Council grants HKU 777908M (Y. Wang) and HKU 779707M (A. Xu), and the Area of Excellent Scheme (AoE/P-10-01) established under the University Grants Committee, HKSAR. Adiponectin knockout mice were kindly provided by Dr. Lawrence Chan at Baylor College of Medicine, who generated these mice with the support of the US National Institutes of Health grant HL-51586. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 137

